Institute of Physiology, University of Zürich and Zürich Center for Integrative Human Physiology, Zürich, Switzerland.
Thromb Res. 2010 Apr;125 Suppl 2:S66-71. doi: 10.1016/S0049-3848(10)70017-7.
Heparin is commonly used for prevention or treatment of cancer-associated thromboembolism. Recent clinical evidence indicates that heparin, and low-molecular weight heparin improves survival of cancer patients. Experimental evidence from various animal models consistently supports the ability of heparin to attenuate metastasis. Heparin, apart from its anticoagulant activity contains a variety of biological activities possibly affecting cancer progression, including: inhibition of heparanase, blocking of P- and L-selectin mediated cell adhesion, and inhibition of angiogenesis. The delineation of antimetastatic activity of heparin is in the focus of several ongoing investigations. This review summarizes the current experimental evidence on the biology of heparin as a potential treatment cancer progression.
肝素通常用于预防或治疗癌症相关的血栓栓塞。最近的临床证据表明，肝素和低分子量肝素可改善癌症患者的生存。来自各种动物模型的实验证据一致表明肝素具有抑制转移的能力。肝素除了具有抗凝活性外，还具有多种可能影响癌症进展的生物学活性，包括：抑制肝素酶、阻断 P 选择素和 L 选择素介导的细胞黏附以及抑制血管生成。肝素的抗转移活性的描绘是几个正在进行的研究的重点。这篇综述总结了肝素作为一种潜在的癌症进展治疗药物的生物学的现有实验证据。
